Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Released By Hunan Huateng Pharmaceutical Co. Ltd
April 19, 2022
Orlistat is a drug designed to treat obesity. The main function of Orlistat is to prevent the absorption of fat from the diet in humans. It prevents the absorption of fat by acting as a lipase inhibitor, ultimately reducing calorie intake. Orlistat works by inhibiting pancreatic and gastric lipase, the enzymes of the pancreas and stomach that break down triglycerides in the intestine. When the activity of lipase is blocked, dietary triglycerides are not hydrolyzed into absorbable free fatty acids, but remain unchanged. Orlistat also helps lower blood pressure and prevents type 2 diabetes in obese people. Orlistat medication does not allow a person to regain lost weight and does not block fat absorption from non-fat foods and sugar.
Huateng Pharma is an ambitious bio-chem company, aiming at offering prime pharma intermediates. In response to the market requirement, Huateng Pharma develops orlistat intermediates CAS NO 104801-96-9.
Huateng Pharma demonstrates outstanding abilities in pharma intermediates. Its pharma intermediates would undergo sophisticated procedures more than a matter of synthesis, including purification, quality inspection, subpackage, quality reinspection, and delivery.
“The market of orlistat enjoys a big growth as increasing number of awareness campaigns for weight management. And in response to this trend, our management decides to introduce a new product line, providing orlistat intermediates CAS NO 104801-96-9 with the most reasonable price,” says the Marketing Chief of Huateng Pharma. ”Previously, we have already been a trust-wothy CDMO for pharmaceutical intermediates, offering custom synthesis and scale up services for many years. We believe our relationship with our partners will be further strengthened after the launch of this popular phamaceutical intermediates.”
About Huateng Pharma
Huateng Pharma is a global provider in contract development and manufacturing for intermediates. With our focus on operational excellence, and the integration of manufacturing operations with EHS, quality assurance, quality control, regulatory, supply chain management and project management, we can manufacture, scale-up and supply high-quality intermediates and APIs from our China facility.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !